CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1)

We evaluated indole-3-lactic acid (ILA), indole-3-acrylic acid (IAA), and indole-3-propionic acid (IPA) in comparison to tapinarof, utilizing C. acnes-stimulated human epidermal keratinocytes and a C. acnes-induced acne mouse model...Collectively, these findings establish ILA as a potent postbiotic that mitigates cutaneous inflammation through selective activation of the AHR. Future studies should prioritize the clinical translation of ILA-based topical formulations, with rigorous evaluation of their efficacy and safety in well-designed human trials, to support their development as a non-antibiotic therapeutic alternative for acne management.

This study demonstrates that common CYP2B6 variants alter testosterone metabolism in a human breast cancer model, potentially disrupting steroid hormone balance and contributing to a tumour-promoting environment. These findings highlight the potential relevance of pharmacogenetic profiling in breast cancer risk assessment.

Compared with parental cells, these resistant cells exhibited reduced sensitivity to paclitaxel, adriamycin, and eribulin in the viability assays. These results suggest that ZSTK3744 combines robust cell growth-inhibitory activity with a favorable safety profile. In conclusion, ZSTK3744 is a promising candidate for overcoming chemotherapy resistance in TNBC, addressing the urgent need for more effective treatment options for this aggressive cancer subtype.

In vivo, 26a synergized antitumor effects with PTX in an A549/PTX xenograft model (41.1% tumor growth inhibition) without evident toxicity. Collectively, 26a represents a novel marine-derived, metabolically stable hCYP1B1 inhibitor with high potential to reverse chemoresistance.

Pathway enrichment analyses highlighted oxidative stress, IL-17, NF-κB, and immune checkpoint signaling. Together, biomass haze-derived PM2.5 from Northern Thailand drives genotype-dependent oxidative stress and transcriptional remodeling in NSCLC cells.

The method exhibited acceptable extraction recovery, matrix effects, and stability, confirming compliance with regulatory standards. The validated method was successfully applied to characterize serum steroid metabolic profiles in both N-methyl-N-nitrosourea-induced breast cancer and ovariectomized rat models, revealing alterations in estrogen 2-hydroxylation and pregnenolone 21-hydroxylation pathways mediated by key steroidogenic enzymes, including CYP1A1/CYP1B1 and potentially CYP21A2-independent mechanisms, providing robust support for preclinical research on steroid-related diseases.

Mechanistically, CYP1B1 activates the AKT/SP-1 signaling pathway to upregulate GPX4 expression, thereby modulating colorectal carcinogenesis and progression. In summary, this study first unveils the crucial role of Calycosin and the CYP1B1-AKT/SP1-GPX4 regulatory axis in CRC ferroptosis, providing novel theoretical foundations for targeted therapy using traditional Chinese medicine-derived small molecules against colorectal cancer.

This study is the first to demonstrate that TAX promotes neuronal differentiation of GSCs by suppressing the CYP1B1-mediated EMT pathway. Our work uncovers a novel mechanism linking CYP1B1 down-regulation to GSC differentiation. These findings establish TAX as a differentiation-inducing agent and propose a new therapeutic strategy for GBM by targeting stemness and EMT concurrently.

In CYP1B1-overexpressing cells, the water-soluble and non-cytotoxic CX-9 (solubility > 100 μM) dose-dependently reversed docetaxel resistance, achieving efficacy at 50 μM comparable to 20 μM of the CYP1B1 inhibitor α-naphthoflavone (ANF). Molecular docking revealed similar binding modes for CX-9 and ANF in CYP1B1's active site. This work hints 2-(2-phenylethyl) chromones as a natural-derived scaffold for promising CYP1B1 inhibitor development.

This study identifies eight tumor mechanics-related genes as prognostic biomarkers for GC through comprehensive bioinformatic analyses. These findings may provide preliminary insights into prognostic assessment and targeted therapy for GC, although further validation with larger sample sizes is required to substantiate their clinical applicability.

Consequently, in path II, the electrophilic addition-rearrangement metabolic process at the C4 site in mode II became the relatively favored metabolic pathway. These results provide theoretical insights into the biological metabolic processes of DMBA and contribute to the comprehension of its toxification potential and cancer risks.

As a bioinformatics analysis, our study indicated that there are possible DEGs in the prostate, such as BMP5 and CYP1B1, which might provide further insight for the pathogenesis of BPH and PCa. However, these findings warrant further validation in prospective, real-world clinical studies.